Start-Up Spotlight: Elypta Targets World’s First Metabolism-Based Early Cancer Diagnosis
Chalmers University of Technology spin out takes a different route to cancer biomarker identification
The Swedish liquid biopsy start-up expects to be the first company to secure US FDA approval for a metabolism-based urine test for the early detection of kidney cancer in post-surgery patients.
You may also be interested in...
Sir Simon Stevens leaves his position as chief executive of NHS England at the end of July after seven years of probably unmatched achievement. His will be big shoes to fill by Amanda Pritchard, his erstwhile deputy.
On this week’s podcast we highlight US Medicare reimbursement topics that industry should keep an eye on, and discuss important regulatory changes underway in the UK.
Cross-industry collaboration is the new focus of EU health care technology research funding activity. Under Horizon Europe, the Innovative Health Initiative will encourage convergence in health technology, and prioritize digital technologies and data analytics. No longer can EU-funded projects be pharma-only or medtech-only, said MedTech Europe’s Patrick Boisseau.